ArticleFrontiers in immunology2026
From associations to clinical practice: translating inflammatory-nutritional indices into a machine learning-driven model for breast cancer risk stratification with cross-ethnic validation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate inflammatory-nutritional indices in relation to breast cancer (BC) risk and mortality and develop a cross-ethnically validated prediction model. Methods: From National Health and Nutrition Examination Survey (NHANES) 2005-2018, 485 BC patients and 16,838 female controls were included, with mortality follow-up through 2019. Weighted multivariate logistic and Cox regression assessed associations between seven inflammatory indices, two composite indicators, and BC risk/mortality. Multiple machine learning (ML) algorithms, including XGBoost, were used to construct risk models. The model was externally validated (NHANES other periods:1999-2004) and cross-ethnic validated. We prospectively enrolled Chinese treatment-naïve breast cancer patients and matched healthy controls for external validation. Results: In fully adjusted models, the Advanced Lung Cancer Inflammation Index (ALI) was inversely associated with BC risk and all-cause mortality (highest vs. lowest tertile: odds ratio [OR] 0.64, 95% CI 0.45-0.91; hazard ratio [HR] 0.41, 95% CI 0.18-0.90). Conversely, neutrophil percentage-to-albumin ratio (NPAR), systemic inflammation response index (SIRI), and neutrophil-to-lymphocyte ratio (NLR) showed positive associations. ALI outperformed other indices in predicting mortality. XGBoost identified NPAR as the top predictive feature; the model incorporating inflammatory indices and age achieved an AUC of 0.832 on the test set, and a web-based dynamic nomogram incorporating these factors was developed. External validation yielded AUCs of 0.781 (NHANES) and 0.730 (Chinese cohort). Conclusions: ALI (protective) and NPAR/SIRI/NLR (detrimental) are robust predictors of BC risk and mortality. The ML model demonstrates good predictive performance, but cross-ethnic validation highlights the need for population-specific calibration, which indicated the potential of ML approaches leveraging inflammatory-nutritional indices to enhance BC risk stratification and inform clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.